1. Profiling Neutrophil–to–Lymphocyte Ratio Changes in Response to Nucleoside Analog Therapy for Chronic Hepatitis B Infection
- Author
-
Amitkumar Patel, Mark N. Wong, Anil B. Seetharam, Myunghan Choi, and Marnonette Marallag
- Subjects
Adult ,Liver Cirrhosis ,Male ,Hepatitis B virus ,Cancer Research ,medicine.medical_specialty ,Cirrhosis ,Neutrophils ,Inflammation ,Subgroup analysis ,Antiviral Agents ,Gastroenterology ,General Biochemistry, Genetics and Molecular Biology ,Virus ,03 medical and health sciences ,Hepatitis B, Chronic ,0302 clinical medicine ,Model for End-Stage Liver Disease ,Internal medicine ,medicine ,Humans ,Hepatitis B e Antigens ,Lymphocyte Count ,Lymphocytes ,Neutrophil to lymphocyte ratio ,Pharmacology ,business.industry ,fungi ,Nucleosides ,Retrospective cohort study ,Middle Aged ,medicine.disease ,Virology ,Liver ,030220 oncology & carcinogenesis ,Cohort ,Female ,030211 gastroenterology & hepatology ,medicine.symptom ,business ,Research Article - Abstract
Background/Aim: The neutrophil–lymphocyte ratio (NLR) has gained attention as an index of inflammation in patients with chronic hepatitis B virus (HBV); however, changes with nucleoside analog therapy require investigation. Patients and Methods: We carried out a retrospective study identifying monoinfected HBV patients initiated on therapy with NLR follow-up over 1 year. Biochemistries recorded at treatment initiation and 1 year included alanine aminotransferase (ALT), Model for End Stage Liver Disease (MELD) score, and NLR. Results: A total of 67 patients were initiated on therapy and had baseline characteristics including e-antigen (eAg) (50, 74.6%) and cirrhosis (19, 28.4%). On subgroup analysis among those with HBV-associated cirrhosis, the NLR decreased over 1 year (3.08±0.39 vs. 1.77±0.18, p
- Published
- 2017
- Full Text
- View/download PDF